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Abstract
Background: Chronic Fatigue Syndrome (CFS) came to attention in the 1980s, but initial investigations did not
find organic causes. Now decades later, the etiology of CFS has yet to be understood, and the role of genetic
predisposition in CFS remains controversial. Recent reports of CFS association with the retrovirus xenotropic murine
leukemic virus-related virus (XMRV) or other murine leukemia related retroviruses (MLV) might also suggest
underlying genetic implications within the host immune system.
Methods: We present analyses of familial clustering of CFS in a computerized genealogical resource linking
multiple generations of genealogy data with medical diagnosis data of a large Utah health care system. We
compare pair-wise relatedness among cases to expected relatedness in the Utah population, and we estimate risk
for CFS for first, second, and third degree relatives of CFS cases.
Results: We observed significant excess relatedness of CFS cases compared to that expected in this population.
Significant excess relatedness was observed for both close (p <0.001) and distant relationships (p = 0.010). We also
observed significant excess CFS relative risk among first (2.70, 95% CI: 1.56-4.66), second (2.34, 95% CI: 1.31-4.19),
and third degree relatives (1.93, 95% CI: 1.21-3.07).
Conclusions: These analyses provide strong support for a heritable contribution to predisposition to Chronic
Fatigue Syndrome. A population of high-risk CFS pedigrees has been identified, the study of which may provide
additional understanding.
Background
The Chronic Fatigue Syndrome (CFS) disease classifica-
tion attempts to identify patients with a condition dis-
tinct from the fatigue of other chronic illness. It is most
frequently defined by the Fukuda definition: severe,
unexplained, chronic fatigu el a s t i n ga tl e a s t6m o n t h s ,
accompanied by 4 of 8 symptom criteria (post-exertional
malaise, impaired memory or concentration, unrefresh-
ing sleep, muscle pain, arthralgia, headaches, sore throat
or, tender cervical or axillary lymph nodes)[1,2]. Accord-
ing to population based studies, 800,000 or more people
in the US meet these criteria [3-8] or have CFS like dis-
ease [8]. The Center for Disease Control (CDC) posts
that the illness costs the US $9 billion annually in lost
earnings and productivity [9,10].
CFS is a complex illness that is not well understood.
This applies to the genetic and environmental origins of
CFS, as well as factors that may contribute to the sever-
ity of symptoms and outcomes. Despite efforts to
develop standardized research criteria to define the dis-
ease, progress in CFS diagnosis and treatment has been
slow, in part due to concurrence in origins, causation,
lack of a standard clinical definition, and lack of specific
biomarkers. A community-based screening study by the
CDC indicated that only 9%-16% of individuals with
CFS had been diagnosed. Variations in presentation (age
of onset, sudden versus gradual onset, and co-morbid
conditions) further increase the heterogeneity of CFS
patients. It has been proposed that predisposition to
CFS may have a genetic basis, although environmental
factors, viral illnesses, stressful life events or traumas
may also be implicated [4,6,8,11,12]. CFS has been
described as a disorder of the brain, the immune system,
or the endocrine system; studies have documented
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these systems [13-18].
There are numerous studies suggesting that genes
might play a role in the development of CFS or in its
progression [19-21]. Several twin studies have examined
genetic vs. environmental determinants of CFS [21-24].
These studies have shown higher concordance in mono-
zygotic vs. dizygotic twins. A small familial aggregation
study (CFS cases = 25), showed excess relative risks for
CFS in first-degree relatives of CFS cases compared to
controls [20].
Analysis of a heritable contribution to CFS is con-
founded by the newness of the diagnosis, the lack of
specific diagnostic criteria or biomarkers, and high rates
of co-morbidity with other syndromes. Here we report
the existence of a unique, population-based resource
with genealogical information linked to diagnosis data
allowing analysis of the genetic relationships among 811
individuals diagnosed with CFS since 1993. The com-
bined data have been analyzed to examine the hypoth-
esis of a heritable contribution to CFS.
Methods
The original Utah Population Database (UPDB) repre-
sented genealogical records of Utah pioneers and their
descendants. The UPDB was created from family group
sheets compiled by members of the Church of Jesus
Christ of Latter-day Saints (LDS) submitted to the Gen-
ealogical Society of Utah. Researchers at the University
of Utah computerized these genealogical paper records
of Mormon pioneers and their descendants into an elec-
tronic database [25].
The original UPDB genealogy represented approxi-
mately1.6 million individuals in genealogies up to 6 gen-
erations deep. Genealogical data added since the original
derives from state records (birth, death, driver’s license
and others) entailing 6.5 million individuals. New indivi-
duals from these sources who link to the original gen-
ealogy data produce pedigrees up to 15 generations
deep with 2.3 million individuals belonging to genealo-
gies at least 3 generations deep.
Numerous Utah data sets have been linked to UPDB
records, including Utah Cancer Registry (UCR) records.
The UPDB has also been linked to individual medical
data from the University of Utah Health Sciences Hospi-
t a l( U U H S H )E n t e r p r i s eD a t aR e s o u r c eC e n t e r .T h e
UUHSH Data Warehouse (DW) contains comprehensive
hospital, medical, and clinical data from 1993 to present.
T h eU U H S Hs e r v e s2 0 %o ft h es t a t e ’s residents. The
UUHSH Data Resource Center currently contains over
1.8 million patient demographic records for patients
treated at the hospital and outpatient clinics. Over 1.26
million (73%) of these hospital records have been
matched to a “person record” in UPDB.
CFS patients were identified by the presence in the
medical record of a CFS-specific ICD-9 diagnostic code
(780.71) originating from medical providers involved in
the patient’s care. Although in other areas of the coun-
t r yt h er a t eo fC F Sd i a g n o s i sm a yb el o w e r ,i ti sl i k e l y
that in Utah the appropriate application of the Fukuda
definition and diagnosis of CFS increases the rate. This
is likely related to the CFS referral clinic in the commu-
nity, and the availability of CFS-specific Continuing
Medical Education to community providers during the
last decade. UUHSH has no clinics specifically devoted
to CFS, or specialists who claim expertise in CFS.
Although all University of Utah hospital and clinic
records have been linked to the UPDB genealogy, only a
selected subset of these records can be accessed, due to
the sensitive nature of the data. A set of randomly
selected hospital patients was identified for use as con-
trols, representing 20% of all University of Utah hospi-
tal/clinic patients who also had linked genealogy data
(n~200,000). We created cohorts to which these
UUHSC patients were assigned, and from which con-
trols were selected randomly. All individuals were
assigned to 1 of 132 cohorts based on sex, birth-year,
and birthplace (i.e., Utah or not). All controls for the
analyses performed were selected randomly from this
set.
This unique resource allowed us to identify all genetic
relationships between patients with a diagnosis of CFS.
To examine evidence for a genetic contribution to CFS
in the UPDB, two different analyses were performed:
estimation of relative risks in close and distant relatives
of CFS cases, and comparison of average relatedness in
CFS cases to controls.
Relative Risks in Relatives
We estimated relative risk (RR) for CFS among the rela-
tives of patients using the classical odds ratio (OR)
m e t h o d .A l t h o u g hw ew e r ea b l et oi d e n t i f ya l lp a t i e n t s
with a diagnosis of CFS, we were only able to identify
20% of all known UUHSC patients in any given cohort,
resulting in an inability to estimate true CFS population
rates. We therefore selected 5 matched (hospital) con-
trols for each case for RR estimation. Because of the
over-representation of cases in each cohort, we excluded
cases from selection as controls.
To estimate the RR we compared the number of CFS
cases among the relatives of cases to the number of CFS
cases among the relatives of 5 independently selected
sets of matched UUHSC controls (relatives counted
without duplication). Because of the nature of the
UPDB resource, and the fact that we identify all genetic
relationships between all CFS cases, this study did not
require any screening of relatives; we identified all rela-
tives of all cases (and all relatives of matched controls)
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cases who were identified among these relatives. The
significance of the test of the null hypothesis RR = 1.0
was determined by Fisher’sE x a c tT e s tf o rt h e2×2
table. Confidence intervals for the RR were estimated as
described in Agresti [26]. This method has been applied
to other disease phenotypes in the UPDB [27,28].
Genealogical Index of Familiality (GIF)
We used the Genealogical Index of Familiality (GIF) sta-
tistic to test the hypothesis of no excess relatedness
among CFS cases. This statistic, developed for use with
the UPDB [29,30], measures the average pair-wise relat-
edness of a set of individuals, and compares the measure
to the average expected relatedness of a set of similar
individuals in this population. In contrast to the RR,
which examines close relationships between cases, the
GIF analysis considers all pair-wise genetic relationships
between all cases, and separately for matched controls.
The GIF relatedness measure for a pair of individuals
implements the Malécot coefficient of kinship [31],
which is defined as the probability that randomly
selected homologous genes from the 2 individuals are
identical by descent from a common ancestor. For par-
ent/child the coefficient is 0.50 (1/2), for siblings or
grandparents the coefficient is 0.25 (1/4), for avunculars
the coefficient is 0.125 (1/8), and so forth. The contribu-
tion to the GIF statistic is smaller for pairs with a
greater genetic distance between them.
The case-GIF statistic is defined as the average of the
coefficients of kinship between all possible pairs of CFS
cases (x 100,000). A control-GIF statistic is calculated as
the average of the coefficients of kinship between all
possible pairs in a single set of randomly selected
matched controls. Comparison of the average related-
ness of a set of cases to the distribution of the average
relatedness statistics estimated for 1,000 independent
sets of matched controls, provides an empirical test of
significance.
Because both close and distant relationships are
observed, the GIF statistic will show excess relatedness
in the presence of genetic effects only, or environmental
(familial, but non-genetic) effects only, or in the pre-
sence of a combination of both effects. The overall GIF
statistic therefore tests the alternative hypothesis of no
excess familial clustering of any origin. We also utilized
the GIF test to examine the more specific hypothesis of
a genetic contribution. To do this, the GIF statistic was
estimated while ignoring all close relationships (relation-
ships with genetic distance < 4, or closer than first cou-
sins). We term this statistic the distant GIF (dGIF). The
dGIF statistic allows a test of the hypothesis that there
are significantly more distant pair-wise relationships
observed among cases than would be expected,
providing strong support for a familial effect that is
based on shared genes.
No patient identifiers were used in this study; analysis
of genetic relationships between affected individuals is
non-identifiable. The University of Utah Institutional
Review Board and the Utah Resource for Genetic and
Epidemiological Research (RGE) approved the utilization
of UPDB data in this study.
Results and Discussion
We identified 941 patients with a CFS diagnosis in the
UUHSC DW from 1993 to present that also had Utah
genealogy data. Age at diagnosis was estimated using
the minimum admission date for a CFS diagnosis, and
thus may be over estimated. Twelve percent of the cases
had an age at diagnosis less than age 20 years; 28% of
the cases had an age at diagnosis greater than 59 years;
653 (69%) were female. Because CFS is associated with
various co-morbid conditions, with possible genetic
associations, we excluded the 130 CFS cases that also
had a diagnosis of cancer in the UCR. This left 811 CFS
cases for analysis.
Relative Risks
Table 1 summarizes the RR estimates risk of CFS among
first, second, and third degree relatives of CFS cases.
For each degree of relationship considered, Table 1
shows the number of relatives considered (for cases and
controls), the number of CFS cases observed among the
relatives (for cases and controls), the significance for the
Fisher’s Exact test, the Odds Ratio (OR) estimate of RR,
and the 95% confidence interval for the RR. Relative risks
for first (RR = 2.70), second (RR = 2.34), and third degree
(RR = 1.93) relatives were significantly elevated.
Genealogical Index of Familiality
Table 2 shows the results of the GIF test for excess
relatedness in the 811 CFS cases, including the average
relatedness of the cases, the mean average relatedness
for 1000 sets of matched controls, the empirical signifi-
cance of the overall test for excess relatedness, and the
empirical significance of the dGIF. The average related-
ness of CFS cases was significantly greater than expected
when all relationships were considered (p <0.001),
Table 1 Estimated RRs for first-, second-, and
third-degree relatives in the 811 CFS cases
Degree
relative
Relatives of:
cases / controls
# CFS cases in
relatives of:
Cases / controls
p-value RR 95% CI
first 5,573 / 28,965 19 / 37 0.001 2.70 1.56, 4.66
second 15,469 / 80,206 16 / 36 0.008 2.34 1.32, 4.19
third 39,766 / 201,717 24 / 64 0.009 1.93 1.21, 3.07
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(due to either shared environment, or shared genes, or a
combination). When close relationships (genetic dis-
tance <4) were ignored, the significant excess was still
present (p = 0.010). Figure 1 displays the GIF test gra-
phically. It shows the contribution to the GIF statistic
(y-axis) by the relationship (x-axis; genetic distance)
between all pairs for CFS cases (and controls). This
observation of significant excess relationships observed
at almost all degrees of relationship strongly supports a
genetic contribution to predisposition to CFS.
Conclusions
The existence of a Utah resource combining up to 15
generations of genealogy data with medical diagnosis
data from 1993 has allowed testing of the hypothesis of
a heritable contribution to CFS. The methods used in
this study have previously provided evidence for a heri-
table component to many diseases, including: prostate
cancer, influenza mortality, aneurysm, cancer, rotator
cuff disease, asthma mortality, and diabetes, among
others [28,32-34]. Studies of Utah high-risk pedigrees
identified in the UPDB have lead to the discovery of
multiple cancer predisposition genes including BRCA1,
BRCA2, p16, and HPC2/ELAC2 [35-38]. The UPDB data
analyzed represents a homogeneous population that has
been shown to be genetically representative of Northern
Europe, with normal U.S. inbreeding levels [39,40].
Significantly increased risks among first degree rela-
tives are often referred to as providing evidence for a
“genetic” contribution to disease. However, given the
sharing among close relatives of their genes, lifestyle,
and environment, increased first degree risk may simply
indicate familial clustering, it does not provide evidence
for a genetic contribution. However, significant excess
risks in second and third degree relatives strongly indi-
cates a genetic contribution to disease, given the much
lower likelihood of these relatives sharing common risks
and environments.
Analysis of CFS in a large Utah resource shows clear
evidence of significant excess familial clustering and sig-
nificantly elevated risks for CFS among first, second,
and third degree relatives of CFS cases. The results
strongly support a genetic contribution to predisposition
to CFS as it is currently defined and diagnosed by clini-
cians in Utah. Although a genetic predisposition to CFS
has been suggested in the literature, this is the first
population-based analysis to comprehensively support
this claim.
This study used a uniform, consistent source for all
diagnoses, and is not limited by bias introduced by
study designs involving selected ascertainment of cases
or requiring recall for diagnoses. The most significant
limitation of this analysis is the narrow window of view
to identify individuals diagnosed with CFS. This results
from the relatively short period of time for which this
diagnosis has existed, and the limited time-period of
diagnosis data available (1993-present). These effects
limit our ability to identify cases who might be related
across different generations (e.g. grandparent/grandchild
or avunculars). Although CFS cases may have been cen-
sored from our observation in this resource, cases are
uniformly censored across the resource, leading to con-
servative, but unbiased, estimates of familiality.
We excluded CFS cases with a cancer diagnosis, which
might have been a cause of CFS symptoms in these
cases. Other potential confounders could not be consid-
ered: including other heritable predisposing conditions
(e.g., depression), or risk factors that are familial, but
not genetic (e.g., occupation, socioeconomic factors, or
healthcare access).
This study of CFS heritability does not allow determi-
nation of the mechanisms that lead to predisposition to
CFS. We have identified multiple pedigrees with a sig-
nificant excess of CFS cases. We propose study of these
pedigrees to identify the gene(s) predisposing to CFS, as
well as to better understand mechanisms and potential
environmental factors and triggers.
Table 2 GIF test for excess relatedness among 811 CFS
cases
Phenotype n Case
Average
Relatedness
Mean
Control
Average
Relatedness
Empirical
p-value
GIF
Empirical
p-value
Distant
GIF
CFS 811 3.15 2.31 < 0.001 0.010
Figure 1 Contribution to the GIF statistic, measuring average
relatedness. Contribution to the GIF statistic (y-axis) by genetic
relationship (genetic distance, x axis) between all pairs of related
CFS cases compared to all pairs of related controls. Genetic distance
1 = parent/offspring, 2-siblings or grandparent/grandchild,
3 = avunculars, and so forth).
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and MLV-related viruses have provided conflicting
results [41-44]. While association of CFS with an infec-
tious-like syndrome at onset is recognized, and many
microbial and viral infections have been implicated as
possible triggers, no single agent has been associated
with a large fraction of cases. It might be hypothesized
that a heritable predisposition to virus infection explains
both our findings and the complex virus associations
that have been recognized.
Identification of CFS predisposition genes, and
increased understanding of how these genes affect
health could allow identification of predisposed indivi-
duals at an earlier age, prophylactic screening for at-risk
individuals, improved healthcare standards to reduce
risk of CFS development, all leading to identification of
treatments or medications that could prevent or delay
onset of symptoms in those impaired by this debilitating
disease.
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